Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study

OBJECTIVE: To compare the recurrence rate of retinopathy of prematurity (ROP) after treatment with 0.3 mg vs. 0.25 mg ranibizumab. SUBJECTS: All patients with ROP who underwent intravitreal injection of ranibizumab in Hainan General Hospital between January 2014 and May 2020 were included in this re...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yingying, Wang, Shaoli, Chen, Siying, Chen, Xingyue, Han, Lizhen, Zhong, Qionglei, Zhang, Kaiyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210651/
https://www.ncbi.nlm.nih.gov/pubmed/35729540
http://dx.doi.org/10.1186/s12886-022-02489-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210651/
https://www.ncbi.nlm.nih.gov/pubmed/35729540
http://dx.doi.org/10.1186/s12886-022-02489-6

Ejemplares similares